Lignin–silver hybrid nanoparticles for nematode and disease control
Harnessing lignin-silver hybrid nanoparticles, this innovative pesticide formulation offers broad-spectrum protection against nematodes and fungi, utilizing biosynthesis for environmental compatibility. The technology is validated and ready for commercial deployment.
Overview
Lignin–silver hybrid nanoparticles represent a cutting-edge solution for managing agricultural pests, particularly nematodes and fungi. The nanoparticles are synthesized using a lignin-mediated biosynthetic process, which not only ensures strong efficacy against pathogens but also guarantees environmental compatibility and sustainability. These nanoparticles offer comprehensive protection against Sudden Death Syndrome (SDS) and Soybean Cyst Nematode (SCN) by releasing silver ions that disrupt cell membranes and metabolism, while the lignin matrix ensures controlled release for prolonged protection.
Technical specifications
- Silver Nanoparticles (Ag-NPs): Synthesized through a lignin-mediated process, acting as both a reducing and stabilizing agent.
- Broad-spectrum efficacy: Effective against a wide range of plant pathogens, with strong antimicrobial and antifungal properties.
- Mechanism of action: Ag⁺ ions bind to enzyme and protein groups, inactivating respiratory and metabolic pathways, while redox cycling generates reactive oxygen species causing oxidative stress and damage.
- Durable protection: Multiple oxidative and physical pathways reduce the likelihood of resistance development.
- Controlled release: Lignin matrix enables sustained release of silver for long-term efficacy.
Technology readiness level
This technology has achieved TRL 9, indicating it is fully validated and ready for widespread commercial deployment. Extensive greenhouse trials and factorial experiments have confirmed its efficacy in managing SCN and SDS, offering optimal pest control and plant health benefits.
About University of Minnesota
The University of Minnesota is a flagship, comprehensive public research university spanning multiple campuses, with a large research enterprise and clinical integration. Industry engages through co-located labs on the Twin Cities campuses, access to an academic health system for clinical translation, and pilot and field-testing facilities that speed scale-up. A statewide extension network and outreach centers provide real-world sites and data partnerships across Minnesota, while proximity to a dense medtech and Fortune 500 corridor enables frequent collaboration. Research is supported by competitive federal funding, including NIH, NSF, DOE, USDA, and DoD. A dedicated technology transfer office manages IP, licensing, sponsored research agreements, and startup incubation to speed commercialization.
delivered to your inbox.